MAIA Biotechnology Prices Public Offering to Raise $30 Million
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 03 2026
0mins
Should l Buy MAIA?
Source: NASDAQ.COM
- Public Offering Pricing: MAIA Biotechnology announced the pricing of its public offering at $1.50 per share for 20 million shares, aiming to raise $30 million to fund clinical trials and general corporate purposes, thereby supporting its research in cancer immunotherapy.
- Stock Price Volatility: Following the announcement, MAIA's stock fell 19.81% in after-hours trading to $1.66, reflecting market concerns over the company's financial health and future prospects, which may impact investor confidence.
- Underwriter Selection: Konik Capital Partners, LLC is the sole book-running manager for the offering, tasked with managing the issuance process to ensure effective capital raising and utilization.
- Clinical Research Progress: MAIA is advancing its lead program, Ateganosine (THIO), in a Phase 2 clinical study for NSCLC patients, with early results indicating that low doses of Ateganosine combined with anti-PD-L1 or anti-PD1 therapy can completely eliminate advanced tumors, showcasing promising therapeutic potential.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MAIA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MAIA
Wall Street analysts forecast MAIA stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.310
Low
14.00
Averages
14.00
High
14.00
Current: 1.310
Low
14.00
Averages
14.00
High
14.00
No data
About MAIA
MAIA Biotechnology, Inc. is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. The Company's THIO (6-thio-dG, 6-thio-2'-deoxyguanosine), is a lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The modified nucleotide 6-thio-2-deoxyguanosine (THIO) induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. THIO-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment with THIO followed by PD-(L)1 inhibitors resulted in tumor regression in advanced, in vivo cancer models by induction of cancer type-specific immune memory. THIO is being developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
MAIA Biotechnology Reports Significant Progress in THIO-101 Trial
- Survival Milestone: In the THIO-101 trial, eight patients survived beyond two years after receiving Ateganosine followed by Cemiplimab, significantly exceeding standard survival expectations for late-stage non-small cell lung cancer patients, indicating the potential breakthrough nature of this therapy.
- Remarkable Efficacy: One third-line patient achieved 33 months of survival, far surpassing the expected 5.8 months, while four second-line patients lived beyond 30 months, well above the documented 10.5-month survival typically seen with chemotherapy or checkpoint inhibitors alone, highlighting the treatment's effectiveness.
- Trial Design Highlights: THIO-101 is a multicenter, open-label Phase 2 study primarily assessing safety and anti-tumor activity, currently expanding into Part C with plans to enroll 48 additional patients in Asia and Europe, demonstrating an acceptable safety profile in a heavily pre-treated population.
- Broad Market Potential: MAIA aims to develop Ateganosine as a second-line or later treatment for non-small cell lung cancer patients, with the global immunotherapy market projected to exceed $50 billion, positioning Ateganosine as a potential entrant with a novel mechanism and differentiated clinical profile.
See More
MAIA Biotechnology Reports Breakthrough in Lung Cancer Treatment
- Significant Survival Improvement: In the THIO-101 clinical trial, eight non-small cell lung cancer patients achieved overall survival beyond two years, with one patient in third-line therapy surviving 33 months, far exceeding the expected 5.8 months, indicating the potential breakthrough efficacy of this treatment.
- Efficacy Validation: Among 24 patients in second-line therapy, survival exceeded 30 months compared to a standard treatment survival of only 10.5 months, suggesting that this treatment regimen could redefine existing standards of care for heavily pre-treated patients.
- Clinical Trial Expansion: The THIO-101 trial is currently enrolling up to 48 participants in Asia and Europe, further validating the safety and efficacy of this therapy, which is expected to provide new treatment options for heavily pre-treated patients.
- Innovative Mechanism: Ateganosine, as the first telomere-targeting agent, demonstrates unique advantages in treating non-small cell lung cancer by inducing specific immune responses and cancer cell death, potentially paving the way for new cancer treatment strategies.
See More
MAIA Biotechnology Completes $30 Million Financing to Advance Clinical Development
- Successful Financing: MAIA Biotechnology completed a $30 million underwritten public offering of 20 million shares at $1.50 each, with proceeds aimed at funding clinical development and strengthening the balance sheet, significantly enhancing the company's capital position to support late-stage clinical execution.
- 2026 Strategic Outlook: The company issued a strategic outlook for 2026, highlighting progress in the THIO program for non-small cell lung cancer, having secured FDA Fast Track designation and initiated the registrational Phase 3 THIO-104 trial in 2025, which is expected to drive future clinical and regulatory catalysts.
- Market Positioning: In the 2026 Letter to Shareholders, MAIA emphasized the breakthrough potential of its therapy in the $50 billion immunotherapy market, particularly addressing the needs of approximately 50,000 patients annually in the third-line setting, showcasing the clinical advantages of its treatment approach.
- Valuation Prospects: Phase 2 data for THIO-101 showed a median progression-free survival of 5.6 months, significantly exceeding standard treatment, and continued positive outcomes will serve as key valuation catalysts for the ongoing THIO-104 Phase 3 study, maintaining a valuation of $10.27 per share.
See More
U.S. Stocks Decline Amid Ongoing Iran-U.S. Conflict
- Dow Jones Plummets: The Dow Jones index fell over 900 points on Tuesday, down 1.85% to 48,002.16, reflecting market sensitivity to geopolitical risks amid the ongoing Iran-U.S. conflict.
- NASDAQ and S&P 500 Decline: The NASDAQ dipped 1.80% to 22,338.43, while the S&P 500 dropped 1.65% to 6,768.35, indicating investor concerns about market outlook.
- Commodity Market Fluctuations: Oil prices surged 8.4% to $77.23 per barrel, driven by supply disruption fears, while gold and silver fell 3.3% and 8.2%, respectively, suggesting a decrease in safe-haven demand.
- European Markets Decline: The eurozone's STOXX 600 index fell 3.2%, and Spain's IBEX 35 index dropped 4.8%, reflecting global market reactions to the downturn in U.S. stocks, which may impact investor confidence.
See More
MAIA Biotechnology Shares Plunge 29% After $30M Offering Announcement
- Offering Size: MAIA Biotechnology priced an offering of 20 million shares at $1.50 each, aiming for gross proceeds of $30 million, which will be allocated for clinical trials and working capital, indicating the company's urgent need for funding.
- Underwriter Option: The company granted underwriters a 45-day option to purchase an additional 3 million shares at the public offering price, a strategy that could further dilute existing shareholders and increase market uncertainty.
- Market Reaction: Following the offering announcement, MAIA's shares fell nearly 29% in premarket trading, reflecting investor concerns about the company's future prospects, particularly in the highly competitive biopharmaceutical sector.
- Closing Timeline: The offering is expected to close on March 4, 2026, subject to customary closing conditions, a timeline that may influence short-term investor decisions and market sentiment.
See More
Ouster Inc Reports Strong Q4 Results, Shares Surge
- Strong Performance: Ouster Inc reported fourth-quarter revenue of $62.18 million, surpassing analyst expectations of $41.1 million, indicating robust market performance that is likely to boost investor confidence.
- Loss Improvement: The company reported a fourth-quarter loss of six cents per share, significantly better than the expected loss of 35 cents, demonstrating substantial progress in cost control and operational efficiency.
- Stock Price Surge: Ouster's shares jumped 13.8% to $23.04 in pre-market trading, reflecting a positive market reaction to its financial results, which may attract more investor interest.
- Optimistic Outlook: Ouster issued first-quarter sales guidance above estimates, signaling strong future prospects that could further drive stock price increases and enhance market confidence in its growth trajectory.
See More
MAIA Biotechnology Reports Significant Progress in THIO-101 Trial
- Survival Milestone: In the THIO-101 trial, eight patients survived beyond two years after receiving Ateganosine followed by Cemiplimab, significantly exceeding standard survival expectations for late-stage non-small cell lung cancer patients, indicating the potential breakthrough nature of this therapy.
- Remarkable Efficacy: One third-line patient achieved 33 months of survival, far surpassing the expected 5.8 months, while four second-line patients lived beyond 30 months, well above the documented 10.5-month survival typically seen with chemotherapy or checkpoint inhibitors alone, highlighting the treatment's effectiveness.
- Trial Design Highlights: THIO-101 is a multicenter, open-label Phase 2 study primarily assessing safety and anti-tumor activity, currently expanding into Part C with plans to enroll 48 additional patients in Asia and Europe, demonstrating an acceptable safety profile in a heavily pre-treated population.
- Broad Market Potential: MAIA aims to develop Ateganosine as a second-line or later treatment for non-small cell lung cancer patients, with the global immunotherapy market projected to exceed $50 billion, positioning Ateganosine as a potential entrant with a novel mechanism and differentiated clinical profile.
See More
MAIA Biotechnology Reports Breakthrough in Lung Cancer Treatment
- Significant Survival Improvement: In the THIO-101 clinical trial, eight non-small cell lung cancer patients achieved overall survival beyond two years, with one patient in third-line therapy surviving 33 months, far exceeding the expected 5.8 months, indicating the potential breakthrough efficacy of this treatment.
- Efficacy Validation: Among 24 patients in second-line therapy, survival exceeded 30 months compared to a standard treatment survival of only 10.5 months, suggesting that this treatment regimen could redefine existing standards of care for heavily pre-treated patients.
- Clinical Trial Expansion: The THIO-101 trial is currently enrolling up to 48 participants in Asia and Europe, further validating the safety and efficacy of this therapy, which is expected to provide new treatment options for heavily pre-treated patients.
- Innovative Mechanism: Ateganosine, as the first telomere-targeting agent, demonstrates unique advantages in treating non-small cell lung cancer by inducing specific immune responses and cancer cell death, potentially paving the way for new cancer treatment strategies.
See More
MAIA Biotechnology Completes $30 Million Financing to Advance Clinical Development
- Successful Financing: MAIA Biotechnology completed a $30 million underwritten public offering of 20 million shares at $1.50 each, with proceeds aimed at funding clinical development and strengthening the balance sheet, significantly enhancing the company's capital position to support late-stage clinical execution.
- 2026 Strategic Outlook: The company issued a strategic outlook for 2026, highlighting progress in the THIO program for non-small cell lung cancer, having secured FDA Fast Track designation and initiated the registrational Phase 3 THIO-104 trial in 2025, which is expected to drive future clinical and regulatory catalysts.
- Market Positioning: In the 2026 Letter to Shareholders, MAIA emphasized the breakthrough potential of its therapy in the $50 billion immunotherapy market, particularly addressing the needs of approximately 50,000 patients annually in the third-line setting, showcasing the clinical advantages of its treatment approach.
- Valuation Prospects: Phase 2 data for THIO-101 showed a median progression-free survival of 5.6 months, significantly exceeding standard treatment, and continued positive outcomes will serve as key valuation catalysts for the ongoing THIO-104 Phase 3 study, maintaining a valuation of $10.27 per share.
See More
U.S. Stocks Decline Amid Ongoing Iran-U.S. Conflict
- Dow Jones Plummets: The Dow Jones index fell over 900 points on Tuesday, down 1.85% to 48,002.16, reflecting market sensitivity to geopolitical risks amid the ongoing Iran-U.S. conflict.
- NASDAQ and S&P 500 Decline: The NASDAQ dipped 1.80% to 22,338.43, while the S&P 500 dropped 1.65% to 6,768.35, indicating investor concerns about market outlook.
- Commodity Market Fluctuations: Oil prices surged 8.4% to $77.23 per barrel, driven by supply disruption fears, while gold and silver fell 3.3% and 8.2%, respectively, suggesting a decrease in safe-haven demand.
- European Markets Decline: The eurozone's STOXX 600 index fell 3.2%, and Spain's IBEX 35 index dropped 4.8%, reflecting global market reactions to the downturn in U.S. stocks, which may impact investor confidence.
See More
MAIA Biotechnology Shares Plunge 29% After $30M Offering Announcement
- Offering Size: MAIA Biotechnology priced an offering of 20 million shares at $1.50 each, aiming for gross proceeds of $30 million, which will be allocated for clinical trials and working capital, indicating the company's urgent need for funding.
- Underwriter Option: The company granted underwriters a 45-day option to purchase an additional 3 million shares at the public offering price, a strategy that could further dilute existing shareholders and increase market uncertainty.
- Market Reaction: Following the offering announcement, MAIA's shares fell nearly 29% in premarket trading, reflecting investor concerns about the company's future prospects, particularly in the highly competitive biopharmaceutical sector.
- Closing Timeline: The offering is expected to close on March 4, 2026, subject to customary closing conditions, a timeline that may influence short-term investor decisions and market sentiment.
See More
Ouster Inc Reports Strong Q4 Results, Shares Surge
- Strong Performance: Ouster Inc reported fourth-quarter revenue of $62.18 million, surpassing analyst expectations of $41.1 million, indicating robust market performance that is likely to boost investor confidence.
- Loss Improvement: The company reported a fourth-quarter loss of six cents per share, significantly better than the expected loss of 35 cents, demonstrating substantial progress in cost control and operational efficiency.
- Stock Price Surge: Ouster's shares jumped 13.8% to $23.04 in pre-market trading, reflecting a positive market reaction to its financial results, which may attract more investor interest.
- Optimistic Outlook: Ouster issued first-quarter sales guidance above estimates, signaling strong future prospects that could further drive stock price increases and enhance market confidence in its growth trajectory.
See More
